| Author | Hempel, L.C.; Lapa, C.; Gaumann, A.; Veloso de Oliveira, J.; Scheiber, J.; Philipp, Patrick; Oyarzun Laura, Cristina; Wesarg, Stefan; Robert, S.; Hempel, D. |
|---|
| Date | 2022 |
|---|
| Type | Journal Article |
|---|
| Abstract | Background: To date, targeted tyrosine kinase inhibitors have been approved for FGFR2 and FGFR3 fusions (pemigatinib and erdafitinib, respectively), but the importance of FGFR2 mutations for transformation activity and as a druggable gene variant with response to different FGFR inhibitors is poorly understood. FGFR2 inhibitors present a mainstay of treatment for locally advanced or metastatic intrahepatic cholangiocellular carcinoma (iCCA). Methods: A 74-year-old male was diagnosed with iCCA in liver segments seven and eight with infiltration of the hepatic veins and inferior vena cava revealed a C382R mutation of the intramembrane domain of FGRR2 receptor. We performed an in-silico study to understand the potential mode-of-action of the mutant FGFR2 targets. Based on experimentally determined structures we then used a structure generated by AlphaFold2 as the variation in question is located at a position not determined well in the experiments. This revealed that the C382R mutation is located in the trans-membranal domain at a position crucial for signal transduction, both for activation and inhibition of downstream-signaling. The Molecular Tumor Board decided to start the treatment with 13.5 mg pemigatinib once daily for 14 days, followed by 7 days of free therapy interval resulting in a sustained partial response. The patient continues to be treated of 13.5 mg as described above. Results: In our case report, we were able to show that the patient in whom an C382R mutation was detected responded to the therapy with pemigatinib. This shows that real-world scenarios differ from the data of the approval studies, thereby illustrating how complex data on patients with FGFR mutations is. One of the main problems of large approval studies is that the functionality of the respective alterations is often disregarded. Conclusions: Our results suggest that respective mutation may be successfully targeted by FGFR-selective tyrosine-kinase inhibitors, demonstrating the importance of the functional characterization of mutations. Legal entity responsible for the study: Louisa Hempel. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest. |
|---|
| Conference | Targeted Anticancer Therapies Congress (TAT) 2022 |
|---|
| Url | https://publica.fraunhofer.de/handle/publica/416571 |
|---|
